|
Last month, Moderna disclosed that its experimental coronavirus vaccine mRNA-1273 is 94.1% effective at preventing COVID-19 infection and has 100% efficacy with regards to stopping severe cases of COVID-19 from developing. That is astonishingly good news, and is just about what we need to end the pandemic. Right now, the development-stage biotech is trading at record highs with its market capitalization hovering around $60 billion. However, there is plenty of room for shares to run even higher.
Moreover, the candidate achieved such efficacy without compromising safety. To date, there have been no serious adverse events reported in its phase 3 efficacy trials. Long-term safety data coming from phase 1 and phase 2 participants have also been very favorable.
Moderna has signed deals with countries across the developed world to provide over 330 million doses of mRNA-1273. The candidate is currently awaiting an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA). A meeting to review its safety and efficacy is scheduled for Dec. 17.
Next year, Moderna expects to produce between 500 million to 1 billion doses of mRNA-1273, which could translate to tens of billions in potential revenue. More critically, its success in developing a coronavirus vaccine candidate serves to validate the concept behind all of its messenger RNA (mRNA) programs. The company has over 20 candidates in development and could generate billions more in revenue on top of what mRNA-1273 has to offer.
The company currently has over $4 billion in cash on its balance sheet and no debt whatsoever. Due to the magnitude of the coronavirus market opportunity, Moderna is arguably one of the best biotech stocks to choose from. Shares are up by over 680% year to date, including a 113% gain in November alone.
Zhiyuan Sun has no position in any of the stocks mentioned.
www.fool.com/investing/2020/12/05/...stocks-to-buy-right-now/
Zitat:
"Du glaubst anscheinend, dass alle bei MODERNA bestellten Vacine auch beliefert werden können?
Nun, da werde ich bereits vom Zocken ausgestiegen sein !!! BioN**** ist ein "Underperformer"
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
4 | 1.101 | MRNA 23$ IPO | Vassago | Randfigur | 15.11.24 18:38 | |
23 | Einige User hier haben ein grundsätzliches Problem | Norbert Nebenwerth | Norbert Nebenwerth | 07.01.24 16:06 | ||
4 | 6 | Danke | Bernd73 | DreamNEON | 04.01.24 09:29 | |
15 | Jetzt hört der Spaß auf | Zerohedge | Namor1 | 19.12.23 19:31 |